Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CACNA1B known ✓ | Q00975 | 1/20 | 0.33 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.32 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16003900 | 0.99 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2TP53POLB | |
| Hydrochloric Acid SCHEMBL16341064 | 0.85 | CKS1B (0.40) | POLBPDE10A | |
| Hydrochloric Acid SCHEMBL16320093 | 0.84 | PDE10A (0.42) | PDE10AGRM5 | |
| SCHEMBL16003898 | 0.84 | CKS1B (0.40) | POLBPDE10A | |
| SCHEMBL16003826 | 0.82 | PDE10A (0.43) | PDE10AGRM5 | |
| SCHEMBL16003886 | 0.77 | NOTUM (0.45) | NPC1RAB9ASMN1; SMN2TP53POLB | |
| SCHEMBL16340966 | 0.75 | PDE10A (0.43) | NPC1RAB9ASMN1; SMN2TP53POLB | |
| SCHEMBL20854927 | 0.74 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2TP53POLB | |
| SCHEMBL16320445 | 0.74 | PDE10A (0.58) | PDE10A | |
| SCHEMBL16003303 | 0.71 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2HRH4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106957317-B | Novel pyrazole derivatives | 持田制药株式会社 | 2019-12-31 | — | — | CN | disclosed |
| US-9777000-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2017-10-03 | — | — | US | disclosed |
| US-20160347751-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-12-01 | — | — | US | disclosed |
| US-9458157-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9453015-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9440970-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| EP-2963037-A1 | NOVEL PYRAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-20150166536-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20150132327-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-14 | — | — | US | disclosed |
| US-20150133448-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-14 | — | — | US | disclosed |
| US-8980888-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8980889-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20140378447-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-12-25 | — | — | US | disclosed |
| US-20140378448-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166536-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | HDAC10 19/4885HDAC6 32/4885CACNA1B 1714/4885 |
| US-20140378447-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | HDAC10 19/4885HDAC6 32/4885CACNA1B 1714/4885 |
| US-20160347751-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | HDAC10 19/4885HDAC6 32/4885CACNA1B 1714/4885 |
| US-20140378448-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | HDAC10 19/4885HDAC6 32/4885CACNA1B 1714/4885 |
| US-20150133448-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | HDAC10 19/4885HDAC6 32/4885CACNA1B 1714/4885 |
| US-20150132327-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | HDAC10 19/4885HDAC6 32/4885CACNA1B 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.